July 22, 2025
Recent research emphasizes the critical role of genetic biomarkers such as FGFR3 and TERT promoter mutations in the improved risk stratification of NMIBC patients. Identifying these genetic markers allows clinicians to more accurately predict disease progression risks and tailor treatments accordingly. Incorporating these biomarkers into clinical practice facilitates personalized medicine approaches, enabling targeted therapeutic interventions for patients identified as high-risk. As biomarker-driven stratification gains broader adoption, it is expected to significantly enhance clinical decision-making, optimize therapeutic efficacy, and improve overall patient outcomes. These advancements underscore a broader shift towards precision oncology, emphasizing individualized patient care based on molecular diagnostics.
Citation: Springer, 2025. Available at: https://link.springer.com
Implication: Emerging biomarkers significantly improve the precision of NMIBC management and patient outcomes.